| 摘要 |
The present invention provides novel compounds of the formula (I)whereinR is selected from the group consisting of R2, R2NH-, or R3R4N-R5- whereinR2 is selected from the group consisting of C9-C12 alkyl,Z is selected from the group consisting of phenyl, heterocycle, cycloalkyl, and naphthanlene; and M is selected from the group consisting of hydrogen, C1-C4 alkyl, andwherein each C9-C12 alkyl or Z is optionally substituted with 1 to 3 substituents, which may be the same or different, and which are selected from the group consisting of D, E,wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy, and C1-C4 alkoxy; each E is independently selected from the group consisting of Hal, OH, and C1-C8 alkyl;R3 and R4 are selected from the group consisting of hydrogen, C1-C4 alkyl and (CH2)y-phenyl, wherein y is an integer 0-8, with the proviso that R3 and R4 not both be hydrogen;R5 is C1-C8 alkylene; andR1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl,and the pharmaceutically acceptable salts, optical isomers, and hydrates thereof,with the proviso that when R2 is the groupwherein n is 1 or greater; R1 is isopropyl or cyclopentyl; R6 is hydrogen, C1-C4 alkyl, or (CH2)m-phenyl; and Z is phenyl, heterocycle, or cycloalkyl, that Z is substituted with 1 to 3 substituents, which may be the same or different, and which are selected from the group consisting ofIn addition, the present invention provides a method of inhibiting cyclin dependent kinases, particularly cdk-2.The present invention also provides a method of preventing apoptosis in neuronal cells and a method of inhibiting the development of neoplasms.
|
